Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series

References

• Gilliland D G, Jordan C T, Felix C A. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004; 80–97
   PubMedGoogle Scholar
• Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Wang Z Y, Sun G L, Lu J X, Gu L J, Huang M E, Chen S R. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouvelle Revue Francaise d Hematologie 1990; 32: 34–36
   PubMedGoogle Scholar
• Estey E, Thall P F, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490
   PubMed Web of Science ®Google Scholar
• Tallman M S, Nabhan C, Feusner J H, Rowe J M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767
   PubMed Web of Science ®Google Scholar
• Zompi S, Legrand O, Bouscary D, Blanc C M, Picard F, Casadevall N, et al. Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t (15;17): a report of two cases and a review of the literature. Br J Haematol 2000; 110: 610–613
   PubMed Web of Science ®Google Scholar
• Au W Y, Lam C C, Ma E S, Man C, Wan T, Kwong Y L. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features. Hum Pathol 2001; 32: 126–129
   PubMed Web of Science ®Google Scholar
• Latagliata R, Petti M C, Fenu S, Mancini M, Spiriti M A, Breccia M, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822–824
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Lopez-Berestein G, Adamson P, Fu C J, Williams A H. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci 2003; 6: 292–301
   PubMed Web of Science ®Google Scholar
• Estey E H, Giles F J, Kantarjian H, O'Brien S, Cortes J, Freireich E J, et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 2230–2235
   PubMed Web of Science ®Google Scholar
• Estey E, Koller C, Tsimberidou A M, O'Brien S, Beran M, Cortes J, et al. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 2005; 105: 1366–1367
   PubMed Web of Science ®Google Scholar
• Thall P, Estey E. Graphical methods for evaluating covariate effects in the Cox model. Handbook of Statistics in Clinical Oncology, J Crowley. Marcel Dekker, New York 2001; 411–432
   Google Scholar
• Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90–95
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192–1200
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14: 1371–1377
   PubMed Web of Science ®Google Scholar
• Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Woods W G, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298–4302
   PubMed Web of Science ®Google Scholar
• Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028
   PubMed Web of Science ®Google Scholar
• Sanz M A, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015–3021
   PubMed Web of Science ®Google Scholar
• Dombret H, Fenaux P, Soignet S L, Tallman M S. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39: 8–13
   PubMed Web of Science ®Google Scholar
• Sanz M A, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237–1243
   PubMed Web of Science ®Google Scholar
• Tallmann M S. Curative therapeutic approaches to APL. Ann Hematol 2004; 83(Suppl 1)S81–S82
   PubMedGoogle Scholar
• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, et al. Use of arsenic trioxide in the treatment of acute promyelocytic leukemia: clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324
   PubMed Web of Science ®Google Scholar
• Soignet S L, Maslak P, Wang Z G, Jhanwar S, Calleja E, Dardashti L J, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617–622
   PubMed Web of Science ®Google Scholar
• Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the MD. Anderson experience. Cancer 2003; 97: 2218–2224
   PubMed Web of Science ®Google Scholar
• Petti M C, Pinazzi M B, Diverio D, Romano A, Petrucci M T, De Santis S, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin. Br J Haematol 2001; 115: 63–65
   PubMed Web of Science ®Google Scholar
• Estey E H, Giles F J, Beran M, O'Brien S, Pierce S A, Faderl S H, et al. Experience with gemtuzumab ozogamycin and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222–4224
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Cimino G, Breccia M, Noguera N I, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995–1999
   PubMed Web of Science ®Google Scholar
• Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003; 8: 132–140
   PubMed Web of Science ®Google Scholar
• de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120–126
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Romano A, Mengarelli A, Diverio D, Iori A P, Moleti M L, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003; 17: 1930–1933
   PubMed Web of Science ®Google Scholar
• Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 2000; 14: 1006–1013
   PubMed Web of Science ®Google Scholar
• Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328–5335
   PubMed Web of Science ®Google Scholar
• Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6(Suppl 1)64–66
   PubMed Web of Science ®Google Scholar